Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 33% primary Improvement Relative Risk c19early.org/cp Ray et al. Conv. Plasma for COVID-19 RCT LATE TREATMENT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 80 patients in India Lower mortality with convalescent plasma (not stat. sig., p=0.34) Ray et al., medRxiv, doi:10.1101/2020.11.25.20237883 Favors conv. plasma Favors control
Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
Ray et al., medRxiv, doi:10.1101/2020.11.25.20237883
Ray et al., Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single.., medRxiv, doi:10.1101/2020.11.25.20237883
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT 80 hospitalized patients in India, 40 treated with convalescent plasma, not showing significant differences in primary analysis. Authors note that significant improvement in hypoxia, reduction in hospital stay, and survival benefit was seen in severe COVID-19 patients with ARDS aged <67. CTRI/2020/05/025209.
risk of death, 33.0% lower, HR 0.67, p = 0.34, treatment 10 of 40 (25.0%), control 14 of 40 (35.0%), NNT 10, adjusted per study, Mantel-Haenszel, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ray et al., 29 Nov 2020, Randomized Controlled Trial, India, peer-reviewed, 37 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20237883; this version posted November 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial Yogiraj Ray1,2*, Shekhar Ranjan Paul1, Purbita Bandopadhyay3, Ranit D’Rozario3, Jafar Sarif3, Abhishake Lahiri4, Debaleena Bhowmik4, Janani Srinivasa Vasudevan5, Ranjeet Maurya5, Akshay Kanakan5, Sachin Sharma5, Manish Kumar5, Praveen Singh5, Rammohan Roy1, Kausik Chaudhury1, Rajsekhar Maiti1,6, Saugata Bagchi1, Ayan Maiti1, Md. Masoom Perwez1, Abhinandan Mondal1, Avinash Tewari1, Samik Mandal1, Arpan Roy1, Moumita Saha1, Durba Biswas7, Chikam Maiti7, Sayantan Chakraborty8, Biswanath Sharma Sarkar1, Anima Haldar1, Bibhuti Saha2, Shantanu Sengupta5, Rajesh Pandey5, Shilpak Chatterjee3, Prasun Bhattacharya7, Sandip Paul4, Dipyaman Ganguly3*. 1 2 Infectious Disease & Beleghata General Hospital, Kolkata, India Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India 3 IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata, India 4 Division of Structural Biology & Bioinformatics, CSIR-Indian Institute of Chemical Biology, Kolkata, India 5 CSIR-Institute of Genomics and Integrative Biology, Delhi, India 6 Department of Pediatrics, Sagar Dutta Hospital & College of Medicine, Kolkata, India 7 Department of Immunohematology & Blood Transfusion, Medical College Hospital, Kolkata, India 8 Department of Critical Care Medicine, Tata Medical Center, Kolkata, India. *Correspondence: Dipyaman@iicb.res.in, jaggs.nbmc@gmail.com 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20237883; this version posted November 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit